Why did Green Cross change strategy over its hemophilia treatment?

Green Cross changed its target of business to the Chinese market, as suspending the U.S. clinical trial of the hemophilia treatment ‘Greengene F,’ which has been conducted since 2012.

The company was known to judge being stubborn on expansion into the U.S. market is not reasonable since the clinical trial in the U.S. is getting delayed and the amount of investment increases. Just in time, sinc...